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ARTICLE
RORγ is a targetable master regulator of
cholesterol biosynthesis in a cancer subtype
Demin Cai 1, Junjian Wang1, Bei Gao2, Jin Li1, Feng Wu3, June X. Zou1, Jianzhen Xu4, Yuqian Jiang1,
Hongye Zou1, Zenghong Huang 1, Alexander D. Borowsky5, Richard J. Bold6,7, Primo N. Lara7, Jian Jian Li 8,
Xinbin Chen 7,9, Kit S. Lam1,7, Ka-Fai To3, Hsing-Jien Kung1,7, Oliver Fiehn 2, Ruqian Zhao10,11,
Ronald M. Evans12 & Hong-Wu Chen1,7*
Tumor subtype-speciﬁc metabolic reprogrammers could serve as targets of therapeutic
intervention. Here we show that triple-negative breast cancer (TNBC) exhibits a
hyper-activated cholesterol-biosynthesis program that is strongly linked to nuclear receptor
RORγ, compared to estrogen receptor-positive breast cancer. Genetic and pharmacological
inhibition of RORγ reduces tumor cholesterol content and synthesis rate while preserving
host cholesterol homeostasis. We demonstrate that RORγ functions as an essential activator
of the entire cholesterol-biosynthesis program, dominating SREBP2 via its binding to
cholesterol-biosynthesis genes and its facilitation of the recruitment of SREBP2. RORγ
inhibition disrupts its association with SREBP2 and reduces chromatin acetylation at
cholesterol-biosynthesis gene loci. RORγ antagonists cause tumor regression in patient-
derived xenografts and immune-intact models. Their combination with cholesterol-lowering
statins elicits superior anti-tumor synergy selectively in TNBC. Together, our study uncovers
a master regulator of the cholesterol-biosynthesis program and an attractive target for TNBC.
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The mevalonate–cholesterol biosynthesis pathway producessterols, isoprenoids, and ubiquinone that are essential fortumor growth. Indeed, deregulated lipid and cholesterol
homeostasis are often associated with tumorigenesis and cancer
progression1. Elevated expression of the cholesterol-biosynthesis
pathway is strongly associated with poor prognosis in the
majority of solid tumors including breast cancer. Intra-tumor
accumulation of cholesterol esters and metabolites is correlated
with tumor cell hyper-proliferation, metastasis, stemness, and
therapeutic resistance2–7. Deregulated cholesterol-biosynthesis
ﬂux or expression of the pathway enzymes could be tumor
driving3,8,9. However, the mechanisms underlying the deregula-
tion are poorly understood.
The cholesterol-biosynthesis pathway is under tight regulation
by transcription factors, such as sterol regulatory element-binding
protein 1 and 2 (SREBP1 and 2) and nuclear receptor (NR) liver
X receptors (LXRs)1,10,11. SREBPs, particularly SREBP2, play a
predominant role in the control of cholesterol biosynthesis. In
response to low cholesterol levels in the endoplasmic reticulum,
SREBP2 is cleaved by proteases. The cleaved, N-terminal portion
of SREBP2 translocates to the nucleus and binds to sterol
response elements (SREs) to activate the expression of
cholesterol-biosynthesis enzymes, such as HMGCR and SQLE. As
membrane cholesterol level increases, less SREBP2 is activated.
This SREBP2-mediated regulatory circuit is believed to be hard-
wired in cholesterol-producing normal tissues and is widely
perceived to function similarly in tumors of most cancer types. In
addition, SREBPs have also been shown to be the downstream
targets and effectors of oncogenic signaling, such as the pRb, Myc,
PI3K-AKT, or mTORC1 pathways1. Intriguingly, gain-of-
function mutant forms of p53 display oncogenic properties
partly through upregulation of SREBP2 targets12. However, little
is understood at the chromatin level how SREBP2 function is
regulated in its activation of the program.
Triple-negative breast cancer (TNBC) tumors feature a high
proliferative index compared with estrogen receptor-α-positive
(ER+) tumors and still lack effective targeted therapy13. Meta-
bolic reprogramming in breast cancer, particularly in lipid and
cholesterol pathways, is still poorly deﬁned and remains to be
exploited for therapeutic targeting14. Recent studies suggest that
circulating cholesterol-lowering drug statins can increase
expression of cholesterol-biosynthesis pathway genes/enzymes in
tumors, likely due to a heightened feedback regulation mediated
by SREBP21,9,15–18. Therefore, strategies to suppress tumor
hyperactive cholesterol-biosynthesis program without induction
of the feedback response are desirable for effective intervention.
In this regard, small molecules, such as fatostatin, that target
SREBP proteins have shown cancer cell-killing effects without the
feedback19. However, their apparent toxicity limits their clinical
use. One major family of lipid metabolic regulators is NRs.
Indeed, promoting tumor cholesterol efﬂux by a LXR agonist has
been shown effective in treating subtypes of glioblastoma5, raising
the possibilities of other NR involvement.
RAR-related orphan receptor gamma (RORγ), together with
related RORα and RORβ, constitutes a subfamily of the NR
superfamily of transcription factors that are attractive therapeutic
targets for metabolic and autoimmune diseases20. RORγ as well as
RORα play important roles in the control of hepatic circadian
rhythmic expression of glucose and lipid metabolic genes21. By
interrogating the distinctions of TNBC in metabolic reprogram-
ming, here we identify RORγ as an essential driver of the
cholesterol-biosynthesis program in TNBC. RORγ inhibition
negates statin-induced, SREBP2-dependent feedback regulation,
and decreases tumor cholesterol-biosynthesis rate without
affecting host cholesterol homeostasis. Therefore, our ﬁndings
deﬁne RORγ as a previously unsuspected master regulator of
cholesterol biosynthesis in cancer metabolism and as an attractive
therapeutic target.
Results
A hyper-activated cholesterol biosynthesis is linked to RORγ.
Tumor gene expression proﬁle analyses have yielded valuable
information for TNBC subtyping and therapeutic targeting,
despite its high heterogeneity. We thus interrogated the
METABRIC dataset (1459 ER+ and 313 TNBC) for major
metabolic pathways that are distinctly altered in TNBC when
compared with ER+ tumors. The analysis showed that the
expression of cell cycle/proliferation genes was elevated more in
TNBC than in ER+ tumors, and that a subset of TNBCs dis-
played aberration in fatty acid oxidation or metabolism (Fig. 1a,
Supplementary Fig. 1a). Notably, one major distinction between
the two tumor types was that the vast majority of TNBCs dis-
played a highly elevated cholesterol-biosynthesis program. In
support of the distinction of TNBC possessing a hyper-activated
cholesterol-biosynthesis program, our metabolomics analysis of a
cohort of tumor tissues (218 ER+ and 33 TNBC) demonstrates
that TNBC tumors had signiﬁcantly higher cholesterol contents
than those of ER+ ones (Fig. 1b).
To identify potential driver(s) of the aberrant cholesterol
biosynthesis in TNBC, we treated TNBC cell MDA-MB468 and
ER+ cell MCF7 with a panel of 31 small molecules targeting the
NR family members and 2 compounds that target SREBP2
translocation regulators SCAP (fatostatin) or S1P (PF-429242)
(Fig. 1c, Supplementary Fig. 1b). As expected, treatment with
fatostatin or PF-429242 strongly decreased the expression of key
cholesterol-biosynthesis genes. Consistent with previous study22,
statin (atorvastatin/ATV) treatment resulted in increases of
cholesterol-biosynthesis gene, due to its relief of the feedback
suppression by cholesterol. As reported5, the LXRα agonists
induced cholesterol efﬂux gene ABCA1 in both TNBC and ER+
cells. Notably, among the NR modulators, two RORγ antagonists
(XY018 and GSK805) displayed the strongest inhibition of all ﬁve
cholesterol-biosynthesis genes in the TNBC cells but not in the
ER+ cells. Although cholesterol precursors or metabolites have
been shown to bind to RORγ and regulate its transcriptional
activity particularly in Th17 cell differentiation23–25, so far RORγ
itself has not been implicated in the direct control of cholesterol
homeostasis. In support of the notion that RORγ is a candidate
driver of the aberrant cholesterol-biosynthesis program in TNBC,
analysis of the METABRIC dataset revealed that the expression of
RORγ gene RORC, but not the other NRs, had a signiﬁcant
positive association with cholesterol-biosynthesis program in
TNBC, not in ER+ tumors (Fig. 1d, Supplementary Fig. 1c–f).
Moreover, expression of RORC, not SREBP2, is linked with poor
overall survival selectively in TNBC (Supplementary Fig. 1g).
Together, these data suggest that cholesterol-biosynthesis pro-
gram is elevated distinctively in TNBC, and that the NR member
RORγ is a candidate driver of the cholesterol-biosynthesis
aberration.
RORγ is a major driver of TNBC cell growth and survival. To
examine the function of RORγ in TNBC, we performed
CRISPR–Cas9 knockout and siRNA knockdown of RORC in
multiple TNBC and other models. As shown in Fig. 2a and
Supplementary Fig. 2a, b, knockout of RORC markedly inhibited
the growth of all six TNBC cell lines examined, but not that of
ER+ MCF-7 or the nonmalignant MCF-10A cells. The knockout
also resulted in a poor survival of TNBC cells as measured with
colony formation and caused pronounced apoptosis as reﬂected
by activation of caspase3/7 (Fig. 2b, c, Supplementary Fig. 2c).
Similarly, siRNA silencing of RORC also signiﬁcantly inhibited
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the TNBC cell growth (Supplementary Fig. 2d). Moreover, RORC
silencing also led to signiﬁcantly decreased expression of proteins
that are important for cell proliferation, growth, and survival,
along with an increased level of cleaved PARP-1 (Supplementary
Fig. 2e). To determine whether elevated RORγ alone is sufﬁcient
to promote the growth and survival of TNBC cells, RORγ
was overexpressed in the TNBC cells. The overexpression sig-
niﬁcantly enhanced the colonogenic growth in regular growth
conditions (Fig. 2d, Supplementary Fig. 2f).
Having demonstrated the crucial role of RORγ in TNBC
cells, we next examined whether its antagonists possess strong
growth-inhibitory effects. GSK805 was demonstrated to be
effective in suppression of Th17 cell differentiation via
antagonizing RORγt26, while XY018 was shown to strongly
inhibit the growth of androgen receptor-positive prostate
tumors via inhibition of tumor cell RORγ27. Both compounds
displayed excellent selectivity toward RORγ28. We treated a
panel of TNBC and ER+ human breast cancer cell lines and
several mouse ER-negative cell lines with the two antagonists
and two RORγ agonists along with the PARP-1 inhibitors
(Fig. 2e, Supplementary Fig. 2g) for comparison. Consistent
with the distinct function of RORγ in TNBC revealed by
our genetic approach, the two RORγ antagonists displayed
strong growth inhibition in most of the human TNBC cells and
the highly metastatic mouse mammary tumor cells (4T1 and
MET-1) (Fig. 2e). In contrast, they had only negligible or
limited growth-inhibition effect on ER+ cells. However,
the protein expression of RORγ in ER+ breast cancer cells is
no less than most of the TNBC cells (Supplementary Fig. 2h).
Similar selectively inhibitory effects of the antagonists on
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Fig. 1 A hyper-activated cholesterol-biosynthesis program is linked to RORγ in TNBC. a Heat map of activity scores of gene expression of indicated
pathways with data normalized from −2 (Green) to 2 (Red) in tumors of TNBC (313 patients) and ER+ cancer (1459 patients). The gene expression
datasets were from METABRIC consortium. For each of the ten metabolic pathways and cell cycle/proliferation pathway, a gene set was manually
compiled, and an “activity score” was represented by the ﬁrst principal component of the gene set for each of the ER+ or TNBC samples. b Relative
cholesterol contents of 33 TNBC tumors and 218 ER+ tumors were measured with GC–TOFMS. Student’s t test. P= 0.0028. c Heat map display of fold
changes (in log2) in cholesterol homeostasis gene expression in MDA-MB468 and MCF-7 cells treated for 48 h by agonists (blue) or antagonists (red) of
indicated NRs. The concentration was 2.5 µM for each compound. The expression of indicated genes was analyzed by qRT-PCR. The experiments were
repeated three times. d Scatter plots showing correlation of transcript expression between RORC and cholesterol-biosynthesis pathway in TNBC and in
ER+ tumors. The Pearson correlation metric was computed by using the ‘cor’ function in R. The METABRIC dataset was used
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the survival of TNBC but not that of ER+ cells were observed
in cell number and colony-formation assays (Fig. 2f, Supple-
mentary Fig. 2i, j). In line with the apoptotic effects by
RORC gene silencing, XY018 and GSK805 strongly elevated
cleaved PARP-1 protein level and the activity of caspase3/7
enzymes and markedly reduced key proliferation and survival
protein expression in the TNBC cells (Supplementary Fig. 2k,
l). Given that 3D organoids may closely mimic clinical tumors
in response to therapeutics, we treated organoids derived
from three different TNBC PDX tumors with the antagonist.
We found that all three organoids were highly sensitive to
XY018 treatment (Fig. 2g, h). Together, these results strongly
support the notion that RORγ is a major driver of TNBC cell
survival.
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RORγ is a master activator of cholesterol biosynthesis. To
identify the core transcriptional program controlled by RORγ in
TNBC cells, we ﬁrst performed RNA-seq analysis of HCC70 and
MDA-MB468 cells treated with antagonists XY018 or GSK805.
Gene ontology (GO) analysis of the 159 transcripts commonly
downregulated by the antagonists in the two TNBC cells revealed
that genes involved in cholesterol-biosynthesis pathway were
among the most highly enriched (Fig. 3a, b). Further examination
by gene-set enrichment analysis (GSEA) also indicated clearly
that hallmarks of cholesterol-biosynthesis pathway were strongly
altered by XY018 or GSK805 (Fig. 3c, Supplementary Fig. 3a).
Cholesterol-biosynthesis program involves at least 21 genes
encoding enzymes to convert acetyl-CoA into cholesterol (Sup-
plementary Fig. 3b). Gene-encoding rate-limiting enzymes
HMGCR and SQLE are commonly deregulated in cancer. Our
pathway-focused analysis demonstrated that the vast majority of
the cholesterol-biosynthesis genes were signiﬁcantly down-
regulated by the RORγ antagonists in a dose-dependent manner
in both TNBC cell lines and tumor organoids (Fig. 3d left two
panels). In contrast, ectopic RORγ strongly increased the
expression of the majority of the pathway genes including
HMGCS1, MVK, and SQLE (Fig. 3d, right panel). Consistently,
treatment with the RORγ antagonists resulted in a strong
downregulation of the proteins including HMGCS1, HMGCR,
MVK, and SQLE (Fig. 3e). Moreover, siRNA silencing of RORγ
also led to a similar downregulation of the cholesterol-
biosynthesis genes and proteins (Supplementary Fig. 3c). In line
with the lack of strong growth or survival-promoting role by
RORγ in ER+ cells, treatment of MCF-7 cells with the antagonist
did not cause any signiﬁcant decreases (Supplementary Fig. 3d).
Importantly, consistent with the effects on gene expression,
inhibition of RORγ by its selective antagonists signiﬁcantly
decreased cellular cholesterol content in the TNBC cells. Likewise,
RORγ silencing also reduced the cholesterol content (Fig. 3f,
Supplementary Fig. 3e). Together, these results support a notion
that RORγ is a previously unrecognized transcriptional activator
of cholesterol-biosynthesis program in TNBC.
RORγ plays a dominant role over SREBP2. As expected, tran-
sient, ectopic expression of the nuclear form SREBP2 effectively
activated the cholesterol-biosynthesis genes (Fig. 3g). However,
treating the cells with the RORγ antagonist after the ectopic
expression not only eliminated the nSREBP2-induced activation
but also resulted in a net repression similar to that observed in
cells only treated with the antagonist, suggesting that RORγ
inhibition is sufﬁcient to completely negate the activation activity
of SREBP2. To examine whether the reverse is true, we silenced
SREBP2 expression with siRNA in cells that ectopically over-
expressed RORγ. Interestingly, knockdown of SREBP2 had
essentially no effect on the activation of the cholesterol-
biosynthesis program by the RORγ (Fig. 3h), suggesting a
SREBP2-independent function of an overexpressed RORγ.
Notably, the antagonists did not affect the level of SREBP2
mRNA or the transcriptionally active, nuclear form SREBP2
protein (Supplementary Fig. 3f, g), suggesting that RORγ may
regulate SREBP2 function at a chromatin level.
RORγ mediates SREBP2 chromatin recruitment and activa-
tion. To deﬁne the mechanism underlying the dominant function
of RORγ over that of SREBP2, we performed ChIP-seq analysis of
RORγ and SREBP2 genome-wide binding in HCC70 cells. The
analysis identiﬁed a total of 31,543 high-conﬁdence binding sites
for RORγ and 48,144 binding sites for SREBP2. Interestingly, the
binding sites of the two proteins are largely overlapping with
86.8% of the RORγ-binding sites shared by SREBP2 and 56.9% of
SREBP2-binding sites co-bound by RORγ (Fig. 4a). GO analysis
of genes that displayed ChIP-seq peaks for both RORγ and
SREBP2 in HCC70 cells revealed that steroid/cortisol synthesis
was among the signiﬁcantly enriched programs (Supplementary
Fig. 4a, b). Transcription factor motif analysis of SREBP2 peak
regions identiﬁed ROREs as one of the top-ranking motifs
(Fig. 4c). Treatment of TNBC cells with the RORγ antagonist
markedly reduced genome-wide SREBP2 association with its
target loci, while little effect was observed in RORγ genome-wide
binding (Fig. 4d). In line with the crucial role of RORγ in con-
trolling cholesterol-biosynthesis program, RORγ antagonists
drastically diminished SREBP2 binding to most of the program
gene loci (Fig. 4e top, Supplementary Fig. 4b left). Indeed, strong
reduction of SREBP2 binding was observed at promoters of the
major targets such as HMGCS1, MVK, SQLE, and DHCR24 in
ChIP-seq and ChIP-qPCR analyses (Fig. 4f top, Supplementary
Fig. 4c, d top). Concomitant with the loss of SREBP2 occupancy,
the transcriptional activation-linked histone mark H3K27ac was
also signiﬁcantly reduced at the chromatin regions (Fig. 4d–f
bottom, Supplementary Fig. 4b right, d bottom, e). The occu-
pancy of SREBP2 coactivator histone acetylase p300 was also
signiﬁcantly decreased by the antagonist (Supplementary Fig. 4e).
In line with the reduction of mRNA levels of cholesterol-
biosynthesis genes, promoter occupancies of RNA Polymerase II
(Pol-II), particularly its transcription initiation-associated CTD-
ser 5 phosphorylated form (S5P Pol-II), were also reduced in the
antagonist-treated TNBC cells.
Next, we examined whether and, if yes, how at the cholesterol-
biosynthesis gene promoter RORγ functions with SREBP2.
Consistent with their genome-wide co-distribution, overlapping
of RORγ- and SREBP2-binding sites was also observed at the
majority of cholesterol-biosynthesis genes (Supplementary
Fig. 4f). ChIP-seq and ChIP-qPCR analyses demonstrated that
indeed RORγ was recruited to the putative RORE sites at
cholesterol-biosynthesis gene promoter regions containing
SREBP2-binding sites (Fig. 4f middle, Supplementary Fig. 4d
middle, g). We then performed reporter-gene assays with
promoters of MVK and HMGCS1 and found that they were
highly responsive to RORγ-mediated transactivation. Mutations
Fig. 2 RORγ is a major driver of TNBC cell survival. a TNBC cells were infected with lentiviruses expressing control sgRNA against GFP or two different
sgRNAs against RORC and Cas9. Three and six days later, viable cell numbers were counted. b TNBC cells were infected as in (a). Fourteen days later,
colonies were counted. c Caspase 3/7 activities were measured by using a luminescent caspase-Glo 3/7 assay kit with TNBC cells harvested 3 days after
the infections as in (a). d TNBC cells were infected by RORγ overexpression or control lentivirus. Fourteen days later, representative images of colony
formation were taken (left) and colonies were counted (right). e Heat map presentation of IC50 for RORγ antagonists GSK805 and XY018, or agonists
SR0987 and LYC55716 in indicated cell lines treated for 4 days. Cell viability was measured with CellTiter Glo on GLOMAX microplate luminometer.
f Indicated cells were treated with vehicle (DMSO) or different concentrations of XY018 and GSK805 for 14 days, after which colonies was counted.
g, h PDX-derived organoids were treated with DMSO or indicated concentrations of XY018. g Six days later, representative images were taken under
a ﬂuorescence microscope (top three rows) or standard light microscope (bottom row). Scale bar represents 20 µM. h Four days later, cell viability in
organoids was measured with CellTiter-Glo. Data are shown as mean ± s.d. n= 3. Student’s t test. **p < 0.01
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of the putative ROREs or treatment with RORγ antagonists
effectively diminished the RORγ-dependent activation (Fig. 4g,
Supplementary Fig. 4h). Together, the data indicate that indeed
RORγ activated SREBP2 target promoters via the putative
ROREs. We then asked whether RORγ can act as a mediator of
SREBP2 transcriptional activation. Co-transfection experiments
show that simultaneous expression of RORγ and nSREBP
resulted in a synergistic transactivation of the MVK gene
promoter, suggesting that RORγ can act as a coactivator of
SREBP2 (Fig. 4h). Finally, we performed co-immunoprecipitation
by using MDA-MB468 cells expressing V5-RORγ and Flag-
nSREBP2 and found that nSREBP2 protein was readily detected
in the immune precipitates of RORγ. Interestingly, the association
could be largely diminished by treating cells with XY018 (Fig. 4i).
Taken together, the results suggest that in TNBC cells, RORγ
plays a dominant role in activating cholesterol-biosynthesis genes
via its own binding to the ROREs at the targets, which in turn
facilitates the recruitment of nSREBP2 to further stimulate the
cholesterol-biosynthesis gene transcription.
RORγ inhibitors synergize with statins in killing TNBC cells.
The prominent role of RORγ in controlling cholesterol-
biosynthesis program prompted us to ﬁrst examine whether its
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antagonistic effect on TNBC cell survival is attributable to cho-
lesterol depletion. Indeed, exogenous cholesterol supply after the
antagonist treatment was effective in preventing cell number
reduction by the two antagonists (Fig. 5a, Supplementary Fig. 5a).
Different from the cholesterol-lowering effect by 2.5 μM XY018
(Fig. 3f, Supplementary Fig. 3e), a lower concentration of XY018
(1.25 μM) had only a marginal effect on the cholesterol content in
the TNBC cells (Fig. 5b, Supplementary Fig. 5b). Likewise, 1.25
μM ATV also had no signiﬁcant effect. However, a combination
of 1.25 μM XY018 and ATV caused a pronounced reduction of
cholesterol content. To examine whether RORγ inhibition can
also synergize with statins in killing TNBC cells, we treated TNBC
cells with a combination of different concentrations of RORγ
inhibitors and statins. Simultaneous treatment of TNBC cells with
increasing concentrations of ATV and XY018 elicited a highly
synergistic inhibition of cell growth (Fig. 5c, Supplementary
Fig. 5c). As expected, a combined treatment of TNBC cells
(HCC70 or MB468) with relatively low concentrations of RORγ
antagonists and statins dramatically reduced their colony for-
mations (Fig. 5d, Supplementary Fig. 5d). In contrast, similar
combinations did not signiﬁcantly affect the colony formations or
cell growth in the MCF-7 cells. Treatment of multiple TNBC
organoid cultures also demonstrated a strong synergistic effect on
cell viability (Fig. 5e, Supplementary Fig. 5e). Different statins
may have different efﬁcacy in inhibition of cancer cell growth and
survival29. When combined with low concentrations of GSK805
or XY018 (at about 1/5 of their IC50), the IC50 values of the widely
used statins (i.e., ATV, simvastatin/SIM, lovastatin, ﬂuvastatin,
and rosuvastatin) all signiﬁcantly dropped approximately three-
to tenfold in all three TNBC cells examined (Supplementary
Fig. 5f), indicating that the growth inhibition synergy is not
speciﬁc to a particular statin drug. Moreover, treating cells with a
low concentration of RORC-speciﬁc siRNAs, was effective in
sensitizing TNBC cells to statin (Supplementary Fig. 5g), sug-
gesting that RORγ inhibition-induced synergy with statin is not
limited to a speciﬁc RORγ antagonist.
RORγ inhibitors negate statin-induced feedback. It has been
postulated that strong induction of SREBP2-dependent feedback
gene activation may underlie the lack of sensitivity to statins by
cancer cells/tumors1. Indeed, our RNA-seq analysis revealed that
cholesterol and sterol biosynthesis pathways are among the most
enriched programs upregulated by statin treatment of TNBC cells
(Supplementary Fig. 5h). We thus reasoned that mitigating statin-
induced feedback might constitute a major mechanism of the
synergy by the combination of statin with RORγ antagonists. We
analyzed gene expressions altered by their singular or combined
treatments using GO and GSEA and found that the cholesterol/
isoprenoid-biosynthesis program is the most signiﬁcantly upre-
gulated by statin alone, but downregulated by the RORγ
antagonists when either alone or in combination with statin
(Fig. 5f–h). Our pathway-focused RNA-seq analysis demon-
strated that indeed co-treatment of TNBC cells with RORγ
antagonists and statin completely abolished the induction by
statin alone of cholesterol-biosynthesis genes (Fig. 5i). Notably,
the co-treatment resulted in a net decrease of the core cholesterol-
biosynthesis enzyme proteins (Fig. 5j). Such superior inhibition
was also observed in the TNBC organoids (Supplementary
Fig. 5i). Conversely, even though statin induced a similar adaptive
activation of cholesterol-biosynthesis program in ER+ cells, the
RORγ antagonist alone only dampened the activation slightly. Its
combination with statin also did not cause any signiﬁcant net
inhibition (Supplementary Fig. 5j). Taken together, the results
support a notion that inhibition of RORγ can completely negate
statin-induced negative feedback and result in strong synergy
with statin in killing TNBC cells.
RORγ inhibitors cause tumor regression and block metastasis.
To examine the therapeutic value of RORγ antagonists, we ﬁrst
treated mice bearing MB468-derived orthotopic xenograft
tumors, i.p., with two different doses of XY018. We found that at
a relatively low dose of 2.5 mg/kg, the antagonist was effective in
inhibition of the tumor growth, while a higher dose (5 mg/kg)
displayed a complete tumor growth blockade for over 7 weeks
(Supplementary Fig. 6a). Similar potent tumor-inhibition activ-
ities of antagonists GSK805 and XY018 at 5 mg/kg were observed
in additional TNBC HCC70 and SUM159 cell-derived xenografts
(Supplementary Fig. 6b, c). To provide data more relevant in a
clinical setting, we measured the oral dosing (p.o.) efﬁcacy of
XY018 in a PDX model of TNBC and found that oral adminis-
tration of XY018 (50 mg/kg) resulted in a tumor regression
(Fig. 6a, Supplementary Fig. 6d). In line with a lack of signiﬁcant
effects on ER+ cell growth, XY018 treatment via i.p. (10 mg/kg)
did not suppress the growth of MCF-7-derived orthotopic
xenografts (Supplementary Fig. 6e).
Next, we examined whether RORγ antagonists have effects on
tumor growth and metastasis in an immune-intact host
environment with 4T1 syngeneic tumors. Similar to the effect
in the xenograft models, the RORγ antagonist strongly inhibited
4T1 tumor growth, and more importantly, dramatically extended
the host animal survival (Fig. 6b, Supplementary Fig. 6f). It is well
known that the 4T1 primary tumor cells at the mammary gland
Fig. 3 RORγ is a master activator of cholesterol biosynthesis in TNBC. a Venn diagram of the number of genes with expression signiﬁcantly (1.5-fold)
downregulated, which is detected by RNA-seq of HCC70 and MDA-MB468 cells treated for 24 h with 2.5 μM XY018 or GSK805. b Gene ontology analysis
of the 159 genes with expression downregulated in both HCC70 and MB468 cells by XY018 and GSK805 treatment as shown in (a). Hypergeometric test
and Benjamini–Hochberg p-value correction. c GSEA plots depicting the enrichment of genes downregulated (1.5-fold) in cholesterol-biosynthesis pathway
in HCC70 cells treated with XY018 (top), or in MDA-MB468 cells treated with XY018 (middle) or GSK805 (bottom). FDR false-discovery rate. d Heat
maps of mRNA expression changes of 21 cholesterol-biosynthesis genes in TNBC cells. Left, mRNA expression of HCC70 treated with XY018 for 24 h was
analyzed by RNA-seq. Middle, mRNA expression of organoids derived from PDX-1079 treated with XY018 for 24 h was analyzed by qRT-PCR. Right,
mRNA expression of MDA-MB468 cells treated with vector control or overexpressed RORC was analyzed by qRT-PCR. n= 3. The experiments were
repeated three times. e Immunoblotting of proteins involved in cholesterol-biosynthesis pathway in MDA-MB468 cells treated with XY018 or GSK805 for
3 days. The experiments were repeated three times. f Total cellular cholesterol contents in HCC70 cells treated with indicated RORγ antagonists (top) or
transfected with siRORC (bottom) for 3 days were analyzed after organic extraction and normalization to protein concentrations. n= 3, data are shown as
mean ± s.d. Student’s t test. ∗∗p < 0.01. g Heat map display of fold changes (in log2) of cholesterol-biosynthesis pathway gene mRNA analyzed by qRT-PCR
in HCC70 cells transfected with nSREBP2 or control vector for 24 h and then treated with XY018 (2.5 µM) or vehicle (DMSO) for another 24 h. n= 3. The
experiments were repeated three times. h Heat map display of fold changes (in log2) of cholesterol-biosynthesis pathway gene mRNA analyzed by qRT-
PCR in RORC-overexpressed MDA-MB468 cells transfected with siSREBP2 or control siRNA for 24 h, n= 3. The experiments were repeated three times.
Source data are provided in a Source Data ﬁle
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metastasize with high efﬁciency to the lung. To examine the
potential effect of the antagonist on tumor metastasis, we
surgically removed the primary tumors at mammary glands and
then treated the mice with XY018 daily for 4 weeks. Histological
analysis revealed that tumor nodules formed in the lung were
signiﬁcantly reduced (Fig. 6c). To further establish the anti-
metastasis activity of targeting RORγ, we used a lung-metastatic
model (LM2) of MDA-MB231. After the animals received LM2
cells via the tail vein, we treated them with XY018 for 4 weeks
before measuring tumor cell bioluminescence and observed a
strong reduction of LM2 lung colonization in the treated mice
(Supplementary Fig. 6g).
RORγ inhibitors in combination with statins regress tumors.
We next evaluated the therapeutic potential of combining RORγ
inhibitors with statins in multiple TNBC models. First, in two
PDX models (1079 and 1173), oral administration of antagonist
XY018 alone (20 mg/kg) signiﬁcantly inhibited the tumor growth,
whereas ATV alone (15 mg/kg, p.o.) did not display any sig-
niﬁcant effect. Remarkably, their combined treatment caused a
tumor regression (Fig. 6d, e, Supplementary Fig. 6h, i). Moreover,
in PDX-1079-bearing animals, combined treatment of the RORγ
antagonist with a different statin drug (SIM) elicited essentially
the same strong synergy (Fig. 6f, Supplementary Fig. 6j). Finally,
in the MDA-MB468 cell-derived xenografts, the combined
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treatment also displayed a synergistic tumor growth inhibition
(Fig. 6g, Supplementary Fig. 6k). Importantly, neither the single
nor the combined treatments affected the animal body weight
over the course of the treatment, suggesting that the RORγ
inhibitor or the combined treatment strategy is relatively safe.
Together, the results from our animal experiments strongly
suggest that RORγ inhibitor alone or its combination with statin
can be a new strategy for effective treatment of TNBC.
RORγ antagonists inhibit TNBC tumor cholesterol biosynth-
esis. Having demonstrated the critical role of RORγ in repro-
gramming of TNBC de novo cholesterol biosynthesis in vitro, we
sought to examine whether RORγ antagonists inhibit tumor
growth through blocking aforementioned reprogramming. We
ﬁrst measured tumor cholesterol content at different time points
after the treatments. Consistent with the in vitro effects, we
observed a marked decrease of cholesterol content in tumors
from mice treated with XY018 or a combination of XY018 and
ATV, for either 2 or 7 days, but not in tumors treated with ATV
alone (Fig. 7a). Notably, co-treatment with XY018 and ATV
caused a signiﬁcantly greater reduction of tumor cholesterol
content when compared with that of XY018 alone. To determine
whether the cholesterol content reduction effects can be attrib-
uted to decreased cholesterol biosynthesis in vivo, we measured
the rate of cholesterol biosynthesis in tumors and in the livers of
host animals by using gas chromatography–mass spectrometry to
quantify the abundance of deuterated hydrogen atoms incorpo-
rated in the newly synthesized cholesterol molecules. In agree-
ment with the reduced cholesterol content in tumors, single-agent
XY018 signiﬁcantly decreased cholesterol biosynthesis rate in the
tumors. XY018 and ATV-combined treatment caused signiﬁcant
reduction more than that of the single agent (Fig. 7b). Consistent
with the rate decrease, tumor mRNA and protein expression of
HMGCS1, MVK, MVD, and SQLE was also signiﬁcantly down-
regulated by XY018 or its combination with statin (Fig. 7c,
Supplementary Fig. 7a). Interestingly, tumor LDLR and ABCA1
expression was not signiﬁcantly changed by the RORγ antagonist.
Together, the results support an interpretation that in TNBC
tumor, inhibition of de novo cholesterol biosynthesis is a pre-
dominant action mechanism of the RORγ inhibitors.
RORγ antagonists preserve host cholesterol homeostasis. To
maintain whole-body cholesterol homeostasis, organs such as the
liver play a major role. Thus, we also measured cholesterol con-
tents of the mouse liver and found that, contrary to the effects in
tumors, the RORγ inhibitor treatments, either alone or in com-
bination with statin, did not signiﬁcantly alter liver cholesterol
content (Fig. 7d). However, as reported in previous studies30,
statin markedly increased the cholesterol-biosynthesis rate in the
liver (Fig. 7e). Consistent with the rate increase, statin strongly
induced liver expression of most of the cholesterol-biosynthesis
genes (Fig. 7f). In contrast to its effects in the tumors, the RORγ
antagonist alone or in combination with ATV did not display any
signiﬁcant inhibition of liver cholesterol-biosynthesis gene
expression (Fig. 7f). Also as reported30,31, statin induced a
reduction of circulating cholesterol. However, such reduction was
not affected by the antagonist (Fig. 7g). Together, these data
indicate that treatment of animals with the RORγ antagonist does
not have any signiﬁcant effect on normal liver function of
maintaining cholesterol homeostasis. The results also point to a
clear distinction in the function of RORγ between TNBC tumors
and the host liver tissue.
To evaluate the overall safety proﬁle of the antagonist and its
combination with statin, we measured the major blood
biochemical and cell parameters in MDA-MB468-bearing SCID
mice after 63 days of the treatments. The results suggest that the
treatment, either alone or with statin, did not cause any
signiﬁcant impairment of complete cell count or function of
liver and kidney (Supplementary Fig. 7b, c). Furthermore, single
or combined therapy did not show any signiﬁcant impacts on
liver histology and organ weight during the course of the
treatment (Supplementary Fig. 7d, e). Together, the data suggest
that treatment with RORγ antagonist alone or in combination
can be efﬁcacious in blocking tumor growth and metastasis
without causing any overt toxicity.
Discussion
Cancer metabolic reprogramming is often context speciﬁc5,32–35.
Here, we show that TNBC exhibits a hyper-activated gene
expression proﬁle of the cholesterol-biosynthesis pathway, which
is even higher than that of ER+ breast cancer. Our search for
possible factors responsible for the distinction led to the
unearthing of RORγ as a master regulator of this metabolic
pathway in TNBC. We demonstrate that RORγ controls virtually
all of the cholesterol-biosynthesis pathway genes that are targets
of SREBP2. Unexpectedly, we found that this function of RORγ is
dominant over that of SREBP2 and that it operates in TNBC but
not in ER+ breast cancer. Together, with the vital role shown by
RORγ in TNBC cell growth and survival and the pronounced
effects displayed by the RORγ antagonists on tumor growth and
metastasis, this study revealed an NR as a previously unsuspected
novel driver of tumor subtype-speciﬁc metabolic reprogramming
and an attractive target for TNBC.
Fig. 4 RORγ plays a dominant role over SREBP2 to reprogram cholesterol biosynthesis. a Venn diagram of the number of high-conﬁdence (FDR 1% and IDR
1%) binding sites shared by RORγ ChIP-seq and SREBP2 ChIP-seq in HCC70 cells. FDR false-discovery rate, IDR irreproducible discovery rate. b Gene
ontology analysis of genes that displayed ChIP-seq peaks for both RORγ and SREBP2 in HCC70 cells. Gene list of each program is shown in Supplementary
Table 1. Hypergeometric and binomial test p value. c Transcription factor (TF) motifs that are enriched in chromatin regions with SREBP2 peaks diminished
by 2.5 µM XY018 treatment of HCC70 for 24 h. d ChIP-seq proﬁles (left) and heat maps of ChIP-Seq signal intensity (right) of SREBP2, RORγ, or H3K27ac
within ±3-kb windows around the center of peak regions in HCC70 cells treated with 2.5 µM XY018 or vehicle for 24 h. e ChIP-Seq proﬁles of SREBP2
(top), RORγ (middle), or H3K27ac (bottom) binding within ±3-kb windows around the center of peak regions on genes involved in cholesterol-biosynthesis
pathway in HCC70 cells treated as in (d). f ChIP-seq signal visualization of SREBP2 (top), RORγ (middle), or H3K27ac (bottom) at representative
cholesterol-biosynthesis genes SQLE and DHCR24 in HCC70 cells treated as in (d). g MVK (wild type or RORE mutated) promoter luciferase reporter
activity changes by RORγ overexpression or treatment with 2.5 µM RORγ antagonists XY018 and GSK805 in MDA-MB468 cells for 24 h. Data are shown
as mean ± s.d. n= 6. Student’s t test. ∗∗p < 0.01. h MVK promoter luciferase reporter activity changes in HEK293T cells co-transfected with RORC,
nSREBP2, or both for 24 h. n= 6. Data are shown as mean ± s.d. Student’s t test. ∗∗p < 0.01. i Co-IP analysis with V5-RORC expressing MDA-MB468 cells
transfected with Flag-nSREBP2 expression vector. Twenty-four hours after transfection, cells were treated with 2.5 µM XY018 or vehicle for another 24 h.
The nuclear extracts were used for co-IP with indicated antibodies. The experiments were repeated three times. Source data are provided in a Source
Data ﬁle
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Fig. 5 RORγ inhibitors strongly synergize with statins in killing TNBC cells. a Exogenous cholesterol supply for 24 h rescued MDA-MB468 cell death caused
by treatment with RORγ antagonists for 24 h. n= 3. b Total cellular cholesterol contents in MDA-MB468 cells treated with indicated RORγ antagonists
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indicated for 2 days. Cell numbers were counted. Blue indicates synergy while red indicates antagonism between drugs. n= 3, the experiments were
repeated three times. d HCC70 cells were treated with indicated concentrations of XY018 or GSK805 alone, or in combination with ATV for 2 weeks.
Representative images of colony formation were taken (left), and colonies were counted (right). n= 3. e Organoids derived from PDX-1079 were treated
with XY018 and ATV as indicated for 3 days. The cell viability was measured with CellTiter-Glo. n= 3. The experiments were repeated three times. f Venn
diagram of the number of genes signiﬁcantly downregulated by XY018 (1.25 μM), or upregulated by ATV (1.25 μM) or downregulated by XY018+ATV in
HCC70 cells treated for 24 h, which were detected by RNA-seq. g Gene ontology analysis of the 100 genes overlapped in expression alterations as shown
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enrichment of genes downregulated (1.5-fold) in cholesterol-biosynthesis pathway in HCC70 cells treated with XY018 (up) or ATV (middle) or both
XY018 and ATV (bottom). FDR false-discovery rate. i Heat maps of mRNA expression changes of cholesterol-biosynthesis genes in cells treated as
indicated for 24 h and analyzed by RNA-seq. j Immunoblotting of proteins involved in cholesterol-biosynthesis pathway in MDA-MB468 cells treated with
vehicle, 2.5 µM XY018, 1.25 µM ATV, or both XY018 and ATV for 3 days. The experiments were repeated three times. Data are shown as mean ± s.d.
Student’s t test. ∗∗p < 0.01. Source data are provided in a Source Data ﬁle
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Despite their heterogeneity at molecular and pathological
levels, most TNBC tumors feature a high proliferative index.
Thus, it is likely that a hyper-activated cholesterol-biosynthesis
program is needed to feed the high demand of membrane lipids
and other metabolites by TNBC tumors for their rapid growth.
The basis for TNBCs to co-opt an activator like RORγ for the
hyper-activation, instead of revamping the established master
SREBP2, is unclear at this point. One advantage might be that
adoption of RORγ can better meet the unique need of TNBC and
at the same time be independent of SREBP-mediated feedback
that is hard-wired in highly differentiated tissues such as the liver.
In support of this notion, ﬁrst, we observed that RORγ plays a
dominant function over that of SREBP2, as overexpressed RORγ
can activate cholesterol-biosynthesis program independent of
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SREBP2, whereas the function of SREBP2 is mediated by RORγ.
Second, we found that RORγ does not mediate statin-induced
feedback for cholesterol- biosynthesis stimulation. Moreover, the
choice of RORγ as a new driver of cholesterol biosynthesis might
also be attributable to the possible unique mode of regulation of
its function. Recent studies show that RORγ can bind to and be
further activated by the intermediates of cholesterol biosynth-
esis23. Therefore, a logical hypothesis will be that by co-opting
RORγ, TNBC cells can effectively enforce their cholesterol-
biosynthesis program with a feed-forward loop. Different from
TNBC, in estrogen-sensitive ER+ tumors, the cholesterol-
biosynthesis program also produces steroid hormones such as
17-β estradiol (E2) to activate ERα for its mitogenic function. In
endocrine therapy-resistant ER+ tumors, cholesterol metabolites
such as 27-hydroxycholesterol (27-HC) can replace E2 to activate
ERα36–38. Therefore, it is possible that in ER+ tumors, ERα can
be a key determinant in cholesterol-biosynthesis reprogramming.
Echoing the TNBC addiction to the function of RORγ,
RORγ-selective antagonists were highly potent in causing
tumor regression and blocking metastasis of multiple TNBC
models, but not of ER+ tumors. Although this study focused
largely on tumor cell-autonomous role of RORγ, our results do
not exclude the possible function of RORγ in the tumor
microenvironment. RORγt, the T-cell-speciﬁc isoform, is
instrumental in eliciting a proinﬂammatory program in mul-
tiple lymphocyte lineages including T helper type 17 (Th17)
and γδT cells. In multiple preclinical models, including 4T1
tumors, tumor-inﬁltrating IL-17-producing γδT and Th17 cells
show potent protumoral functions through their recruitment or
interactions with other immune cells such as neutrophils,
MDSCs, M2 macrophages, and Treg cells, which can lead to
immune suppression, enhanced angiogenesis, and metastasis39–
43. Importantly, high levels of IL-17-producing cell inﬁltrations
are associated with the triple-negative status and shorter
disease-free survival39,41,44. In line with this, we observed that
the RORγ antagonists were also effective in suppressing
metastasis and enhancing survival in the 4T1 immune-intact
model. Moreover, a recent study has shown that inhibition of
cholesterol-biosynthesis pathway induces T-cell responses and
enhances antigen-speciﬁc antitumor immunity45.
The attractiveness of RORγ inhibition as a targeted therapy for
TNBC is also reﬂected by a lack of signiﬁcant impact on host lipid
homeostasis. Statin use at doses for treatment of hypercholes-
terolemia is generally safe. However, its efﬁcacy in an adjuvant
setting as an anticancer drug appears very limited in clinical trials
likely because of the SREBP2-mediated tumor feedback
response18. The strong anti-TNBC synergism displayed by a
combination of RORγ antagonist and statin is a clear manifes-
tation of a potent blockade of the feedback by RORγ inhibition.
In conclusion, our results collectively indicate that the unique
function of RORγ offers a new opportunity for effective treatment
of a cancer subtype with addiction to a hyper-activated choles-
terol-biosynthesis program.
Methods
Cell lines. HCC70, HCC1500, HCC1937, HCC1806, HCC1935, HCC1954, and
ZR75-1 cells were cultured in RPMI1640 supplemented with 10% FBS. MDA-
MB231, MDA-MB468, MDA-MB436, MDA-MB453, MDA-MD231-derived LM2
(4175), MCF-7, MDA-MB361, BT474, and BT20 were cultured in DMEM sup-
plemented with 10% FBS. T47D and BT549 were cultured in
RPMI1640 supplemented with 10% FBS and insulin (10 μg/ml). Hs578T was cul-
tured in DMEM supplemented with 10% FBS and insulin (10 μg/ml). SUM149 and
SUM159 were cultured in DMEM/F12 medium supplemented with 5% FBS and
insulin (10 μg/ml) and hydrocortisone (0.5 mg/ml). 4T1, DB-7, and MET-1 mouse
cell lines were cultured in RPMI1640 supplemented with 10% FBS and insulin.
MCF-10A cells were cultured in DMEM/F12 medium plus 5% horse serum,
cholera toxin (100 ng/ml), EGF (20 ng/ml), insulin (10 μg/ml), and hydrocortisone
(0.5 mg/ml). Cells were grown at 37 °C in 5% CO2 incubators. Cells were obtained
from ATCC, except those indicated below. MDA-MD231-derived LM2 and
4T1 cells were a kind gift from Dr. Joan Massague (Sloan Kettering Institute) and
Dr. Haifa Shen (Houston Methodist Research Institute), respectively. DB-7 and
MET-1 were described previously46. The TNBC cancer cell lines were recently
authenticated by ATCC by using STR proﬁling. Cell lines were regularly tested
being negative for mycoplasma.
Chemicals. Sources for chemicals are as follows: XY018 and GSK805 (purity >
99%) were synthesized by WuXi AppTec. Other chemicals (purity > 98%) are from
Sigma and Selleck unless indicated otherwise.
Organoid culture. Organoids were cultured from PDX xenografts when the tumor
size reached ~500 mm3. Brieﬂy, dissected tumors were ﬁnely minced and trans-
ferred to a 50-ml conical tube, including a digestion mix consisting of serum-free
DMEM/F-12 medium (Gibco) and 1 mg/ml collagenase IV (Sigma), and incubated
for 1 h at 37 °C. Isolated organoids were mixed with 50 μl of Matrigel (BD Bios-
ciences) and seeded in 24-well plates (Greiner bio-one). The culture medium
contains phenol red-free DMEM/F-12 with penicillin/streptomycin/glutamine
(100 mg/ml), primocin (50 mg/ml), Hepes (10 mM), B27 supplement (1 × ), A83-
01 (500 nM), Y-27632 (5 mM), R-Spondin 3 (250 ng/ml), neuregulin 1 (5 nM),
FGF 7 (5 ng/ml), FGF 10 (20 ng/ml), EGF (ng/ml), SB202190 (500 nM), N-
acetylcysteine (1.25 mM), and nicotinamide (5 mM). One milliliter of supple-
mented culture medium was added per well, and organoids were maintained in a
37 °C humidiﬁed atmosphere under 5% CO2.
Mouse models and treatments. NSG (JAX stock #005557) mice were purchased
from the Jackson Laboratory. SCID C. B –17 mice or Balb/c nu/nu athymic mice
were purchased from Envigo. Mice were housed under standard conditions with
free access to food and water, under a 12-h light/12-h dark cycle in a temperature-
controlled environment. Mice were fed a standard rodent chow diet (Envigo Teklad
2918). For cell line-derived xenografts, cells (2 × 106 for each of the human cancer
cells or 3 × 104 mouse 4T1) were mixed with Matrigel as 50% suspension. Then the
cells were injected, in a volume of 0.1 ml, bilaterally into inguinal mammary glands
of 4–6-week-old female C.B-17-SCID mice. For the patient-derived xenograft,
PDX-1079 (JAX ID: TM01079), PDX-9327 (JAX ID: J000099327) and PDX-1173
(JAX ID: J000101173) were purchased from the Jackson Laboratory. PDXs were
propagated by inserting ~2 mm3 into inguinal mammary glands of 4–6-week-old
female C.B-17-SCID mice. Animal group size of six or more was estimated to have
a high statistic power, based on power calculation and previous studies involving
the same xenograft models. The concentrations of drug and the routes of drug
administration are indicated in each ﬁgure. When the tumor volumes reached to
the indicated volume, mice were randomized and then administered with 100 μl of
vehicle (with a formulation of 15% Cremophor EL, Calbiochem, 82.5% PBS, and
2.5% DMSO), statins (in PBS), or RORγ antagonists (in a formulation of 15%
Cremophor EL, 82.5% PBS, and 2.5% DMSO), or their combinations (in their
respective solvent). Tumor volumes were monitored by using calipers with volume
calculated by using the equation: π/6 (length × width2). Body weight and survival
during the course of the study was also monitored. At the end of the studies, mice
Fig. 6 RORγ inhibitors alone or with statins cause tumor regression and block metastasis. a Mice bearing PDX-1079 were treated, p.o., 5 times per week,
with vehicle or 50mg/kg XY018 for 57 days. Tumor volume and representative images are shown. n= 7 mice per group. Student’s t test. ∗∗p < 0.01. mpk,
mg/kg. b K–M survival plot of 4T1 tumor-bearing mice treated with vehicle or XY018 (20mg/kg, i.p.) for 56 days, n= 10. c Lung tumor nodules
metastasized from primary sites were analyzed for 4T1 tumor-carrying mice treated with XY018 (20mg/kg, i.p.) or vehicle daily for 4 weeks.
Representative lung section images were taken with arrows indicating tumor nodules. n= 6. Student’s t test. ∗∗p < 0.01. d, e PDX-1079 and PDX-1173 were
treated, 5 times per week, p.o., with vehicle, 20mg/kg XY018 alone, 15 mg/kg ATV alone, or both XY018+ATV for indicated days. Volumes (left) and
weights (right) are shown. n= 7. Student’s t test. ∗∗p < 0.01. f PDX-1079 was treated, 5 times per week, p.o., with vehicle, 20mg/kg XY018 alone, 15 mg/
kg simvastatin alone (SIM), or both XY018+ SIM for 47 days. Volumes are shown. n= 7. Student’s t test. ∗∗p < 0.01. g Mice bearing MDA-MB468 were
treated, 5 times per week, p.o., with vehicle, 20mg/kg XY018 alone, 15 mg/kg ATV alone, or both XY018+ATV for 32 days. Volumes are shown. n= 7.
Student’s t test. ∗∗p < 0.01
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Fig. 7 RORγ inhibitor reduces TNBC tumor cholesterol biosynthesis in vivo. a Total tumor cholesterol content from HCC70 tumor-bearing mice with
indicated treatments for 2 or 7 days was analyzed after organic extraction. n= 12–14 tumors per group. b Labeled isotope ratio indicating tumor cholesterol
biosynthesis rate was measured with GC–MS quantifying deuterated hydrogen incorporation into the newly synthesized cholesterol molecules. HCC70
tumor-carrying mice were treated with XY018, ATV, or both as indicated, then dosed with deuterium oxide for 2 h before tissues were collected. n= 7 mice
per group. c Heat map display of fold changes (in log2) of cholesterol-biosynthesis pathway gene mRNA analyzed by qRT-PCR in tumors from HCC70
tumor-bearing mice with indicated treatments for 7 days. n= 7, the experiments were repeated three times. d Total liver cholesterol content from mice in
(a) with indicated treatments for 7 days. n= 7. e Labeled isotope ratio of liver cholesterol biosynthesis rate in the mice as in (b). n= 7. f Heat map display
of fold changes (in log2) of cholesterol-biosynthesis pathway gene mRNA analyzed by qRT-PCR in livers from TNBC tumor-bearing mice with indicated
treatments for 7 or 63 days. n= 7, the experiments were repeated three times. g Total cholesterol levels in serum from mice as in (f) were measured. From
a to g, 20mg/kg XY018 or 15 mg/kg ATV were used. Data are shown as mean ± s.e.m. Student’s t test. ∗p < 0.05, ∗∗p < 0.01, NS not signiﬁcant
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were killed, and tumors were dissected and weighed. In addition, the organs and
whole blood were harvested.
For effects on lung metastasis from orthotopic 4T1 murine tumors, female Balb/
c mice were inoculated with 4T1 cells (3 × 104) into the inguinal mammary gland
fat pad. Once the tumors reached 250 mm3 at the primary sites they were surgically
removed. Mice were then treated daily with XY018 (20 mg/kg, i.p.) or vehicle for
4 weeks. For histological analysis, mice were euthanized at the end of the
treatments, and tumor nodules in the lungs were analyzed by H&E staining for
morphology.
For effects on lung colonization, 2 × 105 luciferase-expressing MDA-MB231-
LM2 (4175) cells were injected into each nude mouse via the tail. The mice were
treated daily with vehicle or 20 mg/kg XY018, i.p. for 4 weeks. Tumor growth in the
lungs was monitored for bioluminescence with a Xenogen IVIS-200 system.
The animal procedures were approved by the Institutional Animal Care and
Use Committee (IACUC) of the University of California, Davis.
Cell viability, apoptosis, and colony formation. For cell viability, cells were
seeded in 96-well plates at 1500–2500 cells per well in a total volume of 100 μl of
media. After 4 days of incubation, Cell-Titer Glo reagents (Promega) were added,
and luminescence was measured on GLOMAX microplate luminometer (Pro-
mega), according to the manufacturer’s instructions. All experimental points were
set up as sextuplicate as biological replication, and the entire experiments were
repeated three times. The data are presented as percentage of viable cells with
vehicle-treated cells set as 100. The estimated in vitro IC50 values were calculated
by using GraphPad Prism 8 software. Caspase-3/7 activity was measured by using a
luminescent caspase-Glo 3/7 assay kit (Promega Corporation, Madison, USA),
following the manufacturer’s instructions. For cell growth, cells were seeded in 6-
well plates at 2 × 105 per well and treated as indicated. Total viable cell numbers
were counted with a Coulter cell counter. For colony formation, 500–1000 cells
were seeded in a well of 6-well or 10-cm plates and cultured for 14 days with the
medium changing every 3 days. When the cell clone grew visible, the medium was
removed, and the cells were ﬁxed with 10% formalin for 10 min. Then the plates
were washed with PBS two times, and the cell colonies were stained with 0.2%
crystal violet (in 10% formalin) for 15 min. The numbers of cell colonies were
counted after washing 5 times by PBS. The above assays were performed in tri-
plicates, and the entire experiments were repeated three times.
Organoid viability. For organoid viability, organoids were seeded in 96-well plates
at 300–500 organoids in 10 μl of Matrigel per well in a total volume of 100 μl of
media. Serially diluted compounds in 100 μl of media were added to the cells 12 h
later. After 4 days of incubation, Cell-Titer Glo reagents (Promega) were added,
and luminescence was measured. All experimental points were set up as sex-
tuplicate as biological replication. The data are presented as percentage of viable
cells with vehicle-treated cells set as 100.
After 6 days of incubation, medium was carefully aspirated and 100 μl of live/
dead reagents (Thermoﬁsher Scientiﬁc) was added followed by 30 min of
incubation at room temperature. Fluorescence microscope was used to capture
images of calcein AM (494/517 nm) to represent the live cells, of ethidium bromide
homodimer-1 (528/617 nm) to identify the dead cells. The above assays were
performed in triplicates. The entire experiments were repeated three times.
qRT-PCR and western blotting analysis. Total RNA was isolated from cells or
xenograft tumors or mouse livers. The cDNA was prepared, ampliﬁed, and mea-
sured in the presence of SYBR as previously described with modiﬁcation27. Brieﬂy,
the ﬂuorescent values were collected, and a melting-curve analysis was performed.
GAPDH was used as the internal reference to normalize the relative level of each
transcript. Fold difference was calculated. The experiments were performed at least
three times with data presented as mean values ± s.d. The primers are shown in
Supplementary Table 2.
Cell lysates were analyzed by immunoblotting with antibodies speciﬁcally
recognizing indicated proteins. The antibodies used are shown in Supplementary
Table 3. The source data of the uncropped immunoblots are provided in the Source
Data ﬁle.
siRNA transfection and lentivirus production. siRNAs for gene knockdown were
purchased from Dharmacon. The siRNA target sequences for RORC were pub-
lished previously27. siRNA against SREBP2 was purchased from Santa Cruz Bio-
technology (sc-36559). Transfections were performed with OptiMEM (Invitrogen)
and Dharmafectin#1 (Dharmacon) following the manufacturer’s instruction. For
RORγ overexpression, human RORγ cDNA in pLX304 (DNASU) was ampliﬁed
and cloned into a modiﬁed pLX304 vector with a V5 tag at the receptor N ter-
minus. Lentiviral particles were produced in 293T cells after co-transfection of the
above lentivirus vectors, psPAX2 and pMD2.G in 10-cm dishes.
CRISPR/Cas9 sgRNA design and lentivirus infection. sgRNAs were designed by
using the MIT CRISPR design software (http://crispr.mit.edu). Oligos corre-
sponding to the sgRNAs were synthesized and cloned into lentiCRISPR v2 vectors
following lentiCRISPRv2 and lentiGuide oligo-cloning protocol (Addgene, plas-
mid#52961). The sgRNA sequences are as follows: GFP,
GGGCGAGGAGCTGTTCACCG; sgRNA-1, GATACCCTCACCTACACCTT;
sgRNA-2, GTGGGGCTGTCCAAGTGACC. Lentiviral particles were produced in
293T cells as in our previous study27. TNBC cancer cells were plated at 2 × 105 cells
per well in 6-well plates. Sixteen hours later, 1 ml of virus-containing supernatant
with 10 ng of polybrene was added to the cells. After 4–6 h, the medium was
changed to regular medium and cultured for another 72 h before harvesting for cell
number and protein expression analysis.
RNA-seq alignment and analysis. HCC70 or MDA-MB468 cells were treated
with vehicle, the antagonists of XY018 (1.25 or 2.5 µM) or GSK805 (2.5 µM), ATV
(1.25 µM), or the combination of antagonists and ATV for 24 h before RNA
extraction. RNA-seq libraries from 1 μg of total RNA were prepared by using
Illumina Tru-Seq RNA Sample Prep Kit, according to the manufacturer’s
instructions. Libraries were validated with an Agilent Bioanalyzer (Agilent Tech-
nologies, Palo Alto, CA). Sequencing was performed on an Illumina HiSeq
2000 sequencer at BGI Tech (Hong Kong). The FASTQ-formatted sequence data
were analyzed by using a standard BWA–Bowtie–Cufﬂinks workﬂow. Sequence
reads were mapped to GRCh37/hg19 assembly with BWA and Biotie software. The
Cufﬂinks package was used for transcript assembly, quantiﬁcation of normalized
gene and isoform expression, and analysis of different expression. Gene Set
Enrichment Analysis (GSEA v.3.0) was applied to rank genes based on the
shrunken limma log2 fold changes. The GSEA tool was used in “pre-ranked”model
with default parameters.
Measurement of cholesterol contents in tissues and cells. Cells or xenograft
tumor tissues were washed three times with cold PBS and subjected to extraction
with organic solvents (7:11:0.1, chloroform/isopropanol/Triton X-100). Total
cholesterol levels were measured by using Amplex™ Red Cholesterol Assay Kit
(Thermoﬁsher Scientiﬁc) and normalized to protein concentrations. Total cho-
lesterol in serum was measured by an enzymatic colorimetric method by using a
commercial kit (Wako) according to the manufacturer’s instructions. All experi-
mental points were set up as triplicate as biological replication. The entire
experiments were repeated three times. The cohort of breast cancer tumor tissues
was previously described47. Their cholesterol contents were analyzed by using gas
chromatography followed by time-of-ﬂight mass spectrometry (GC–TOFMS) as
described before48. Raw GC–TOFMS data were preprocessed by ChromaTOF
version 2.32 for baseline subtraction, deconvolution, and peak detection. Speciﬁ-
cally, 3-s peak width, baseline subtraction just above the noise level, and automatic
mass spectral deconvolution and peak detection at signal/noise levels of 5:1
throughout the chromatogram were used. Binbase algorithm was used for anno-
tation and relative quantiﬁcation of cholesterol with the following settings: validity
of the chromatogram 107 counts/s, unbiased retention index marker detection, MS
similarity > 800, retention index calculation by ﬁfth-order polynomial regression,
retention index window 2000 units, and validation of unique ions and apex
masses49,50.
Analysis of cholesterol-biosynthesis rate in tumor and liver. SCID mice bearing
HCC70 tumors were treated with indicated drugs for 2 days and then injected with
99% deuterium oxide (Cambridge Isotope Laboratories, 23.3 mg/g; i.p.). After 2 h,
the mice were terminated under anesthesia; the liver and tumor were excised.
Samples (10 mg) were extracted with 1 mL of extraction solvent, 3:3:2 acetonitrile,
isopropanol, and water. The extraction solvent was pre-cooled at −20 °C. Samples
were homogenized by using Genogrinder at 500 × g for 30 s, shaken for 5 min at 4 °
C, and centrifuged for 2 min at 20,000 × g. Five-hundred microliters of supernatant
was dried overnight. Ten microliters of methoxyamine hydrochloride was added to
each dried sample followed by shaking at 30 °C for 1.5 h. Ninety-one microliters of
N-tert-Butyldimethylsilyl-N-methyltriﬂuoroacetamide (MTBSTFA, Sigma-Aldrich,
St. Louis, MO) was added to each sample followed by shaking at 70 °C for 60 min
for tert butyldimethylsilylation. Agilent 7200 GC-accurate-mass QTOF (Agilent,
Santa Clara, CA) was used for data acquisition. Agilent J&W DB-5ms Ultra Inert
column was used (Agilent, Santa Clara, CA). The column was held at 60 °C for 0.5
min, ramped to 325 °C at 10 °C/min, and held at 325 °C for 10 min. Raw data were
processed by using Agilent Mass Hunter Quantitative Analysis software for QTOF
(B. 07.00).
Co-immunoprecipitation (Co-IP). Cells were washed three times and then lysed
with lysis buffer (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.4% NP-40,
and protease inhibitor cocktail) for 30 min at 4 °C. The homogenates were cen-
trifuged for 30 s at 15,000 × g at 4 °C. The supernatant was removed. The pellets
were lysed in extraction buffer (20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA,
and protease inhibitor cocktail) for 15 min for nuclear extract collection. Magnetic
beads (Thermoﬁsher Scientiﬁc) were incubated with indicated antibodies at 4 °C
for 2 h. Five percent of the nuclear extracts were harvested for western blot analysis
as inputs. The remaining cell lysates were incubated with the pre-treated beads
overnight at 4 °C. The immunoprecipitation beads were washed with wash buffer
(50 mM Tris-HCl, pH7.5, 200 mM NaCl, 5 mM EDTA, and 1% Triton X-100) ﬁve
times, followed by western blotting analysis. The source data of the uncropped
immunoblots are provided in the Source Data ﬁle.
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Reporter constructs and reporter-gene assay. Transient transfection and
reporter-gene assays were performed as previously described27, with the following
modiﬁcations. For reporter-gene assays of cholesterol-biosynthesis genes, pGL3-
MVK-wt and pGL3-HMGCS1-wt were constructed by inserting the DNA frag-
ments of the MVK promoter from −787 to+ 279 or the HMGCS1 promoter from
−1288 to+ 70 into pGL3-basic luciferase reporter vector. The mutant form pGL3-
MVK-mu of pGL3-MVK-wt contains sequences mutated from ATTGGTCAC to
ATTAACGTC. The mutant form pGL3-HMGCS1-wt contains sequences mutated
from TCTGACCA to TCCCGTTA. Cells (HEK293T) were co-transfected with
pLX304-RORγ or pcDNA3.1-SREBP2 (Addgene, plasmid#26807) with wild type or
mutant forms of MVK or HMGCS1 promoter reporter constructs. The renilla
plasmid was co-transfected for normalization. After 12 h of incubation, cells were
treated with vehicle or RORγ antagonists as indicated, for another 24 h. The
luciferase was then analyzed with a Dual-Luciferase Assay system (Promega) on a
luminometer according to the manufactuer's instruction. All transfections were
performed in sextuplicate, and each experiment was repeated at least three times.
ChIP-qPCR, ChIP-seq, and data analysis. Brieﬂy, HCC70 cells were treated with
vehicle or XY018 (2.5 μM) for 24 h before they were subjected to cross-linking in
1% formaldehyde for 5 min, followed by quenching with glycine for 5 min on ice.
Cells were pelleted by centrifugation and resuspended in lysis buffer (50 mM
HEPES, pH 8.0, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, and 0.25%
Triton X-100). The pellets were then resuspended in washing buffer (10 mM Tris,
pH 8.0, 1 mM EDTA, 0.5 mM EGTA, and 200 mM NaCl), washed, and resus-
pended in shearing buffer (0.1% SDS, 1 mM EDTA, pH 8, and 10 mM Tris-HCl,
pH 8) before sonication by using Covaris E220 following the manufacturer’s
instruction. Chromatin fragments were precipitated by using speciﬁc antibodies
and Protein G beads, washed, and treated with Proteinase K and RNAse A. Puriﬁed
ChIP DNA was then used for ChIP-qPCR analysis and library generation.
The antibodies used for the ChIP-qPCR assay are SREBP2 (Cayman,
10007663); RNAPII (Santa Cruz; sc-899); RNAPII-S5P (Active Motif; #39749);
RNAPII-S2P (Active Motif; #61083); H3K27ac (Abcam; ab4729); p300 (Abcam;
ab10485); IgG (Santa Cruz; sc-2027). ChIPs were performed with each
experimental point in triplicate, and each experiment was repeated three times. The
primers are shown in Supplementary Table 2.
Libraries were quantiﬁed with the Bioanalyzer 2100 (Agilent) and sequenced in
single-end 50-bp mode on the Illumina HiSeq 2000 Sequencer (BGI, Hong Kong).
Antibodies used were against SREBP2 (Cayman, #10007663) and H3K27ac
(Abcam; ab4729). Anti-RORγ rabbit serum was described previously27. The
speciﬁcity data for the anti-RORγ antibody used in ChIP-seq are shown in the
Source Data.
Fastq ﬁles from ChIP-seq were processed by the pipeline of AQUAS
Transcription Factor and Histone (https://github.com/kundajelab/
chipseq_pipeline). Brieﬂy, sequencing tags were mapped against the Homo sapiens
(human) reference genome (hg19) by using BWA 0.7.1551. Uniquely mapped tags
after ﬁltering and deduping were used for peak calling by model-based analysis for
ChIP-Seq (MACS; 2.1.0) to identify regions of enrichment over background.
Normalized genome-wide signal-coverage tracks from raw-read alignment ﬁles
were built by MACS2, UCSC tools (bedGraphToBigWig/bedClip; http://
hgdownload.cse.ucsc.edu/admin/exe/linux.x86_64/), and bedTools (https://github.
com/arq5x/bedtools2). Visualization of the ChIP-seq signal at enriched genomic
regions (avgproﬁle and heatmap) was achieved by using deepTools (https://
deeptools.readthedocs.io/en/develop/index.html). Peak-associated genes were
identiﬁed by using the annotatePeaks function of HOMER (http://homer.ucsd.edu/
homer/index.html). Each of the RORγ or SREBP2-binding sites were assigned to
the nearest gene. Further annotation information includes whether a peak is in the
TSS (transcription start site, from −1 kb to+ 100 bp), TTS (transcription
termination site, from −100 bp to+ 1 kb), Exon (Coding), 5′ UTR Exon, 3′ UTR
Exon, Intronic, or Intergenic. Venn diagrams of enriched genomic regions and
associated genes were generated by Intervene52. GO analysis was performed by
using ClueGO53 and BINGO54.
Motif analysis. DNA segments from SREBP2-binding site of vehicle or XY018
(2.5 μM) treatment were extracted. The segments were used for motif analysis by
homer script ﬁndMotifGenome.pl with argument “hg19-p32” to detect enrichment
of de novo and known TF motif. Homer results were further manually analyzed.
Those motifs with high background enrichment and possible false positives were
removed.
Bioinformatic analyses with data from clinical tumors. METABRIC data sets for
1459 ER+ and 313 TNBC samples were downloaded from cBioPortal website at
http://www.cbioportal.org/study?id=brca_metabric#summary. The data were then
Log2 transformed and quantile normalized before further analysis. For each of the
10 metabolic pathways and cell cycle/proliferation pathway, a gene set was
manually compiled. An “activity score” was represented by the ﬁrst-principal
component of the gene set for each ER+ or TNBC samples. Principal-component
analysis (PCA) was carried out with R ‘COMPADRE’ package55. Differences in
pathway activity between ER+ and TNBC groups were calculated by using two-
sided Student’s t tests. After PCA transformation, the samples were visualized
according to pathway activity score by using “gplots” R packages. Based on the
pathway activity score and the gene proﬁle across the samples, the Pearson cor-
relation metric was computed between each gene (i.e., RORC) and each metabolic
pathway by using the “cor” function in R.
The prognostic value of RORC gene characteristic with survival was determined
by Kaplan–Meier analysis by using KM-plotter online software (http://kmplot.
com/analysis/).
Kaplan–Meier estimates of the relationship between gene expression and distant
metastasis-free survival were calculated by setting the software to look for the
optimal cutoff for separation of patients into high- and low-expressing groups. The
hazard ratio, log-rank P value, and number of patients in each group are shown on
the KM plot for each gene.
Morphology. Sections (5 μm, 10 sections per sample) of liver or tumor tissues from
tumor-bearing mice with or without treatment, were ﬁxed in 10% phosphate-
buffered formalin, stained with hematoxylin/eosin Y, and visualized by using a light
microscope with a 20 × objective.
Serum analysis. Whole blood was collected via cardiac draw in Sarstedt 100-μL
K3E EDTA tubes. The collected blood was immediately analyzed for complete
blood count by using HemaVet 950FS (Drew Scientiﬁc). All biochemical serum
evaluations used to investigate organ functions were performed at the same time to
minimize analytical variability and determined on a Roche Integra 400 Plus ana-
lyzer (Roche Diagnostics).
Statistical analysis. Statistical analyses were performed by GraphPad Prism
software 8.0. All statistical details of experiments are included in the ﬁgure legends
or the speciﬁc Methods section.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All data supporting the ﬁndings of this study are available within the article and
Supplementary Information, or from the corresponding author upon request. The source
data underlying Figs. 3e, 4i, 5j and Supplementary Figs. 2e, f, h, k, 3c, d, g, 7a are provided
as a Source Data ﬁle. All RNA-seq and ChIP-seq data generated in this study are
deposited in the Gene Expression Omnibus (GEO) database under the accession
numbers “GSE131856” and “GSE126380”. A reporting summary for this article is
available as a Supplementary Information ﬁle.
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